Journal Article10.1053/GAST.2002.34242
Endocannabinoids as physiological regulators of colonic propulsion in mice
Luisa Pinto,Angelo A. Izzo,Maria Grazia Cascio,Tiziana Bisogno,Karen Hospodar-Scott,David R. Brown,Nicola Mascolo,Vincenzo Di Marzo,Francesco Capasso +8 more
TL;DR: Endocannabinoids acting on myenteric CB1 receptors tonically inhibit colonic propulsion in mice, and high amounts of 2-arachidonylglycerol and particularly anandamide were found in the colon, together with a high activity of an andamide amidohydrolase.
read more
About: This article is published in Gastroenterology. The article was published on 01 Jul 2002. The article focuses on the topics: Anandamide amidohydrolase activity & Cannabinoid receptor.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
TL;DR: A comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy is provided.
2K
The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research
Eric Groce
- 01 Dec 2018
TL;DR: Despite increased cannabis use and a changing state-level policy landscape, conclusive evidence regarding the shortand long-term health effects—both harms and benefits—of cannabis use remains elusive.
The endocannabinoid system and its therapeutic exploitation
TL;DR: The conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come are explored.
1.1K
Control of pain initiation by endogenous cannabinoids
Antonio Calignano,G. L A Ranna,Andrea Giuffrida,Daniele Piomelli +3 more
- 01 Jan 1999
TL;DR: In this article, anandamide attenuates the pain behavior produced by chemical damage to cutaneous tissue by interacting with CB1-like cannabinoid receptors located outside the central nervous system.
918
Cannabinoid-based drugs as anti-inflammatory therapeutics
TL;DR: A wealth of information indicates that marijuana-derived cannabinoids have immunosuppressive and anti-inflammatory properties, and on the basis of this mode of action, the therapeutic usefulness of these drugs in chronic inflammatory diseases is now being reassessed.
741
References
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.
TL;DR: It is reported that mast cells express both the gene and a functional CB2 receptor protein with negative regulatory effects on mast cell activation, and palmitoylethanolamide and its derivatives may provide antiinflammatory therapeutic strategies specifically targeted to mast cells.
664
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity
TL;DR: It is shown for the first time that, despite the overlap between the chemical moieties of AMT inhibitors and VR1 agonists, selective inhibitors of AEA uptake that do not activate VR1 can be developed.
354
Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function.
Tiziana Bisogno,Fernando Berrendero,Gerolmina Ambrosino,M. Cebeira,J.A. Ramos,J.J. Fernández-Ruiz,V. Di Marzo +6 more
TL;DR: The hypothesis that, in the brain, AEA is a metabolic product of NArPE and may reach levels compatible with its proposed neuromodulatory function is supported.
327
Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation
Angelo A. Izzo,Filomena Fezza,Raffaele Capasso,Tiziana Bisogno,Luisa Pinto,Teresa Iuvone,Giuseppe Esposito,Nicola Mascolo,Vincenzo Di Marzo,Francesco Capasso +9 more
TL;DR: It is concluded that inflammation of the gut increases the potency of cannabinoid agonists possibly by ‘up‐regulating’ CB1 receptor expression; in addition, endocannabinoids, whose turnover is increased in inflamed gut, might tonically inhibit intestinal motility.
Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret
Marja D. Van Sickle,Lorraine D. Oland,Winnie Ho,Cecilia J. Hillard,Ken Mackie,Joseph S. Davison,Keith A. Sharkey +6 more
TL;DR: CB1r mediates the anti-emetic action of cannabinoids in the dorsal vagal complex and is found in the myenteric plexus of the stomach and duodenum and a novel neuroregulatory system involved in the control of emesis.
245